The collaboration will focus on delivering protein therapeutics across the blood-brain barrier. Under the terms of the agreement, Immusoft will receive an undisclosed upfront payment and research funding support. The company is also eligible to receive future option fees and milestone payments with a total potential value of more than $900 million.
Immusoft is eligible for tiered royalties on future products resulting from the partnership, and Takeda would be responsible for further preclinical and clinical development and commercialization.
Copyright © 2021 scienceboard.net